Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials

The Pediatric Infectious Disease Journal
Laura L KovandaWilliam W Hope

Abstract

Neonatal candidiasis causes significant morbidity and mortality in high risk infants. The micafungin dosage regimen of 10 mg/kg established for the treatment of neonatal candidiasis is based on a laboratory animal model of neonatal hematogenous Candida meningoencephalitis and pharmacokinetic (PK)-pharmacodynamic (PD) bridging studies. However, little is known about the how these PK-PD data translate clinically. Micafungin plasma concentrations from infants were used to construct a population PK model using Pmetrics software. Bayesian posterior estimates for infants with invasive candidiasis were used to evaluate the relationship between drug exposure and mycologic response using logistic regression. Sixty-four infants 3-119 days of age were included, of which 29 (45%) infants had invasive candidiasis. A 2-compartment PK model fits the data well. Allometric scaling was applied to clearance and volume normalized to the mean population weight (kg). The mean (standard deviation) estimates for clearance and volume in the central compartment were 0.07 (0.05) L/h/1.8 kg and 0.61 (0.53) L/1.8 kg, respectively. No relationship between average daily area under concentration-time curve or average daily area under concentration-time curve:...Continue Reading

References

Feb 27, 2004·Journal of Perinatology : Official Journal of the California Perinatal Association·Daniel K BenjaminReese H Clark
Nov 18, 2004·JAMA : the Journal of the American Medical Association·Barbara J StollUNKNOWN National Institute of Child Health and Human Development Neonatal Research Network
Aug 17, 2005·Infectious Disease Clinics of North America·P Brian SmithDaniel K Benjamin
Jan 7, 2006·Pediatrics·Daniel K BenjaminUNKNOWN National Institute of Child Health and Human Development Neonatal Research Network
Nov 30, 2006·The Pediatric Infectious Disease Journal·Gloria P HeresiGregory L Kearns
Aug 6, 2008·The Pediatric Infectious Disease Journal·Flavio Queiroz-TellesUNKNOWN Micafungin Invasive Candidiasis Study Group
Mar 26, 2009·The Pediatric Infectious Disease Journal·P Brian SmithDaniel K Benjamin
Nov 6, 2009·Clinical Pharmacology and Therapeutics·D K BenjaminT J Walsh
Mar 24, 2010·Antimicrobial Agents and Chemotherapy·William W HopeDaniel K Benjamin
Sep 30, 2010·Pediatrics·Daniel K BenjaminUNKNOWN Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
Feb 11, 2011·Expert Opinion on Drug Safety·Oliver A CornelyAndrew J Ullmann
Mar 8, 2011·The Pediatric Infectious Disease Journal·Antonio C ArrietaAndreas H Groll
Feb 4, 2012·The Pediatric Infectious Disease Journal·Nasrullah A UndreAntonio Arrieta
Mar 15, 2012·The Pediatric Infectious Disease Journal·Kevin M WattDaniel K Benjamin
Jan 4, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O A CornelyUNKNOWN ESCMID Fungal Infection Study Group
Jan 4, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·W W HopeUNKNOWN ESCMID Fungal Infection Study Group
Jan 4, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A J UllmannUNKNOWN ESCMID Fungal Infection Study Group
Jan 22, 2014·Pediatrics·Sofia AliagaP Brian Smith
Nov 26, 2014·Antimicrobial Agents and Chemotherapy·William W HopeDaniel K Benjamin
Jan 22, 2015·Archives of Disease in Childhood. Fetal and Neonatal Edition·P ManzoniE Castagnola
Feb 14, 2015·Clinics in Perinatology·Matthew S KellyP Brian Smith
Sep 26, 2015·Journal of the Pediatric Infectious Diseases Society·Christine M SalvatoreThomas J Walsh
Jan 19, 2016·Current Fungal Infection Reports·Amanda B Arsenault, Joseph M Bliss
Aug 12, 2016·Clinical Pharmacokinetics·Elisa A M CalvierCatherijne A J Knibbe

❮ Previous
Next ❯

Citations

Aug 31, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David Andes

❮ Previous
Next ❯

Software Mentioned

MYSTAT
SAS
Pmetrics

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.